The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and limitations of a specific immunotherapy in chronic hepatitis B
Open accessAbstract
BACKGROUND/AIMS: This controlled study aimed to evaluate the efficacy and potential side effects of hepatitis B virus (HBV) vaccination as active immunotherapy in HBV-related chronic hepatitis. METHODS: The 118 included patients were 'naive' subjects who had never received any previous anti-HBV therapy, showed detectable serum HBV DNA and had biopsy-proven chronic hepatitis. In a 12-month follow-up they were given either five intramuscular injections of 20 microg of a preS2/S (GenHevac B, Pasteur-Mérieux) (n = 46) or an S vaccine (Recombivax Merck & Co.) (n = 34) or no treatment as a control (n = 37). The efficacy of vaccination was evaluated by testing for serum HBV DNA negativation using a standard liquid hybridization assay. RESULTS: Three months after the first three vaccine injections, the percentage of serum HBV DNA negativation was higher in the vaccine groups (16.3%) than in the control group (2.7%) (P = 0.033, by the chi2 Pearson test) and was more frequently observed in patients who had pretreatment viremia >200 pg/ml (none in the control group vs. 16.7% in the vaccinated groups) (P = 0.025). After 12 months follow-up and five vaccine injections, there was no difference in the rate of serum HBV DNA negativation between vaccinated and unvaccinated subjects but HBV vaccines significantly decreased the HBV viral load between the sixth and twelfth months (P = 0.04) in contrast with the control group. The rate of HBe/anti-HBe seroconversion after 6 months of follow-up occurred only in eight (13.3%) vaccinated patients and in one (3.6%) of the controls. Disappearance of serum HBsAg was not observed in any of the patients. CONCLUSIONS: This controlled study offers direct evidence that the HBV vaccine may decrease HBV replication in chronic hepatitis B patients. It also emphasizes the need for reinforced immunization strategies as well as combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
Cited by
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Ghozy, S., Nam, N. H., Radwan, I., Karimzadeh, S., Tieu, T. M., Hashan, M. R., Abbas, A. S., Eid, P. S., Vuong, N. L., Khang, N. V., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2089 · Cited by 32
Metadata
- Authors
- Pol, S., Nalpas, B., Driss, F., Michel, M.-L., Tiollais, P., Denis, J., & Bréchot, C.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2001-06
- Volume
- 34
- Issue
- 6
- Pages
- 917-921
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2111629931
- Cited by
- 182
- References
- 1
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. https://app.cochat.ai/papers/10.1016/s0168-8278(01)00028-9
- The paper
- Pol, S., Nalpas, B., Driss, F., Michel, M.-L., Tiollais, P., Denis, J., & Bréchot, C. (2001). Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(01)00028-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.